Eradivir develops antibody-recruiting small molecules that selectively target diseased cells to activate a precise immune response for elimination. Their Bispecific Antigenic immuno-Therapy (BAiT) technology links immune cells directly to the diseased cell for rapid and selective destruction. This platform aims to create pharmaceuticals for treating various conditions, including viral infections and cancer.
Funding
$20.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antiviral therapies often struggle to effectively eliminate both free-floating viruses and cells already infected, leading to prolonged illness and potential for further spread, particularly in the case of rapidly mutating viruses like influenza and coronaviruses. Existing treatments may also have limited efficacy against late-stage viral infections when the viral load is high and the immune system is overwhelmed.
Solution
Eradivir is developing Bispecific Antigenic immuno-Therapy (BAiT) drugs that redirect a patient’s immune cells to target and eliminate both free viruses and virus-infected cells. These small molecule immunotherapies tether immune cells specifically to diseased cells, facilitating rapid and selective destruction of the virus and infected cells. Eradivir's platform utilizes ligands with high specificity for viral targets, such as the influenza virus's neuraminidase, and recruits the body's innate immune system by linking infected cells to anti-hapten antibodies. This approach elicits a potent immune response and inhibits virus reproduction, offering a potentially more effective treatment, even in advanced infections. The modular platform allows for the development of therapies against a wide variety of disease states, including other respiratory viruses and non-viral infections.
Target Audience
The primary target audience includes patients infected with viral diseases, such as influenza and other respiratory viruses, and the healthcare providers who treat them.
Features
- Small molecule-based Bispecific Antigenic immuno-Therapy (BAiT) technology
- Ligands with high specificity for viral targets, such as a unique domain of the spike protein in coronaviruses or the neuraminidase of influenza
- Immunologic payloads linked to targeting ligands to elicit a response from cytotoxic immune cells
- Recruits the innate immune system by linking infected cells to anti-hapten antibodies
- Modular platform applicable to a wide variety of disease states beyond viral infections
- EV25, the lead molecule for influenza, has demonstrated single-dose efficacy and an extended therapeutic window in preclinical models
- Phase 1 and Phase 2a clinical trials for EV25 are underway